Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (13174)	9/28/2004 4:11:29 PM
From: keokalani'nui	Read Replies (3) \| Respond to of 52153

Anybody have a stock symbol list, or as close to a complete list as is possible, of every public biotech in the world? A list they would be willing to share?

To: Rudy Saucillo who wrote (13174)	9/28/2004 7:45:48 PM
From: IRWIN JAMES FRANKEL	Respond to of 52153

>>BTW, the ESPR and AGIX end points were the same...regression of plaque volume. And if memory serves me the IVUS readings for the ESPR study were taken Nissen's group. He shows up again as the researcher doing the AGIX readings (for part of the study). ij

To: Rudy Saucillo who wrote (13174)	9/29/2004 8:26:48 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

>> agree with Rick's comments in that I wouldn't short this stock << No problem, but I didn't say that. I said that shorts should be praying (given capitalization relative to projected market size, and that supportive data is on the table). But I'd also be praying, if I were a long. Michael is correct.... the data isn't from a complete study, and it's not great that so many scans had to be tossed. Peter is correct...... two expert groups read blind and "read significant". There's encouraging data on the table. I don't have an opinion re. the company or the project.